Clinical Efficacy of Tumor Antigen-Pulsed DC Treatment for High-Grade Glioma Patients: Evidence from a Meta-Analysis

Abstract

BackgroundThe effectiveness of immunotherapy for high-grade glioma (HGG) patients remains controversial. To evaluate the therapeutic efficacy of dendritic cells (DCs) alone in the treatment of HGG, we performed a systematic review and meta-analysis in terms of patient survival with relevant published clinical studies.Materials and methodsA total of 409 patients, including historical cohorts, nonrandomized and randomized controls with HGG, were selected for the meta-analysis.ResultsThe treatment of HGG with DCs was associated with a significantly improved one-year survival (OS) (p<0.001) and 1.5-, 2-, 3-, 4-, and 5-year OS (p<0.001) compared with the non-DC group. A meta-analysis of the patient outcome data revealed that DC immunotherapy has a significant influence on progression-free survival (PFS) in HGG patients, who showed significantly improved 1-,1.5-, 2-, 3- and 4-year PFS (p<0.001). The analysis of Karnofsky performance status (KPS) demonstrated no favorable results for DC cell therapy arm (p = 0.23).The percentages of CD3+CD8+ and CD3+CD4+ T cells and CD16+ lymphocyte subset were not significantly increased in the DC group compared with the baseline levels observed before treatment (p>0.05), whereas CD56+ lymphocyte subset were significantly increased after DC treatment (p = 0.0001). Furthermore, the levels of IFN-γ in the peripheral blood of HGG patients, which reflect the immune function of the patients, were significantly increased after DC immunotherapy (p<0.001).ConclusionsThus, our meta-analysis showed that DC immunotherapy markedly prolongs survival rates and progression-free time, enhances immune function, and improves the efficacy of the treatment of HGG patients.

Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy

“…Dendritic Cell-Based Cancer Immunotherapy after the demonstration of survival gains in DC-treated cancer patients in a number of trials Cao et al, 2014;Wang et al, 2014). The foremost example is sipuleucel-T (Provenge; Dendreon Corporation, Seattle, WA), the first and currently the only DCbased immunotherapeutic that received approval from the U.S. Food and Drug Administration.…”

“…Cell-Based Cancer Immunotherapy: The Acute Myeloid Leukemia Showcase A growing body of evidence indicates that DC vaccination can be of clinical benefit to cancer patients (Draube et al, 2011;Anguille et al, 2014;Cao et al, 2014;Wang et al, 2014), encouraging the further development of this form of immunotherapy. Nevertheless, there is a general agreement among cancer researchers that the true clinical potential of DCbased cancer immunotherapy has not been attained yet (Bot et al, 2013;Datta et al, 2014).…”

Dendritic cell immunotherapy for brain tumors

“…DCs loaded with tumor-derived mRNA or cancer stem cell antigens have also been studied [26]. An ongoing Phase I trial is currently examining the applicability of a vaccine utilizing mRNA-loaded DCs (NCT00890032) for patients with gliomas.…”

Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis

“…Systematic analysis of nine Phase I and II trials, covering 409 patients and analyzing the clinical efficacy of dendritic cell treatment for high-grade gliomas, by Cao et al34 demonstrated that dendritic cell immunotherapy significantly improves patient OS and progression-free survival, but with no significant difference in Karnofsky performance status (quality of life assessment) when compared to control groups. Furthermore, no dose-related toxicity has been found to be associated with dendritic cell vaccination 30.…”